Pfizer Inc. reaffirmed its full-year 2026 guidance, projecting Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00. This reaffirmation follows the disclosure of the company's Chief Financial Officer transition. Pfizer Inc. is a biopharmaceutical company that develops, manufactures, and markets medicines and vaccines.

Chief Financial Officer Dave Denton will step down from Pfizer Inc. on August 15, 2026, to pursue a role in the consumer goods industry. The company stated his departure is unrelated to financial results or disagreements regarding accounting or reporting policies. Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer effective August 16, 2026, while a search for a permanent successor is conducted. Pfizer is a pharmaceutical company that develops and manufactures medicines.